Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 55287L101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Frazier Life Sciences Public Fund, L.P.
13D/A
|
11.7% |
8/10/2026
Event 8/6/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 3.0% | |||
| FHMLSP, L.P. | 3.0% | |||
| FHMLSP, L.L.C. | 3.0% | |||
| Frazier Life Sciences X, L.P. | 10.8% | |||
| FHMLS X, L.P. | 10.8% | |||
| FHMLS X, L.L.C. | 10.8% | |||
| Frazier Life Sciences XI, L.P. | 0% | |||
| FHMLS XI, L.P. | 0% | |||
| FHMLS XI, L.L.C. | 0% | |||
| James N. Topper | 11.7% | |||
| Patrick J. Heron | 11.7% | |||
|
FMR LLC
13G/A
|
11.2% |
7/8/2026
Event 6/30/2026
|
||
| FMR LLC | 11.2% | |||
| Abigail P. Johnson | 11.2% | |||
|
Wellington Management Group LLP
13G/A
|
10.5% |
7/8/2026
Event 6/30/2026
|
||
| Wellington Management Group LLP | 10.5% | |||
| Wellington Group Holdings LLP | 10.5% | |||
| Wellington Investment Advisors Holdings LLP | 10.5% | |||
| Wellington Management Company LLP | 9.8% | |||
|
New Enterprise Associates 17, L.P.
13D/A
|
8.1% |
11/10/2025
Event 11/6/2025
|
||
| New Enterprise Associates 17, L.P. | 8.1% | |||
| NEA Partners 17, L.P. | 8.1% | |||
| Nea 17 GP, LLC | 8.1% | |||
| Forest Baskett | 8.1% | |||
| Ali Behbahani | 8.1% | |||
| Carmen Chang | 8.1% | |||
| Anthony A. Florence, Jr. | 8.1% | |||
| Mohamad H. Makhzoumi | 8.1% | |||
| Edward T. Mathers | 8.1% | |||
| Scott D. Sandell | 8.1% | |||
| Paul Walker | 8.1% | |||
| Rick Yang | 8.1% | |||
|
Orbimed Advisors LLC
13D/A
|
6.4% |
8/10/2026
Event 8/6/2026
|
||
| Orbimed Advisors LLC | 6.4% | |||
| Orbimed Capital GP VII LLC | 5.2% | |||
| Orbimed Genesis GP LLC | 1.2% | |||
| BlackRock, Inc. 13G | 5.5% |
7/29/2026
Event 6/30/2026
|
||
|
Paradigm Biocapital Advisors LP
13G
|
5.2% |
6/24/2026
Event 6/16/2026
|
||
| Paradigm BioCapital Advisors LP | 5.2% | |||
| Paradigm BioCapital Advisors GP LLC | 5.2% | |||
| Senai Asefaw, M.D. | 5.2% | |||
| Paradigm BioCapital International Fund Ltd. | 4.6% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
Norwest Venture Partners XVI, LP
13D/A
|
4.8% |
9/30/2025
Event 9/26/2025
|
||
| Norwest Venture Partners XVI, LP | 4.8% | |||
| Genesis VC Partners XVI, LLC | 4.8% | |||
| NVP Associates, LLC | 4.8% | |||
| Jeffrey Crowe | 4.8% | |||
| Jon Erik Kossow | 4.8% | |||
| Tiba Aynechi | 4.8% | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 13G/A | 4.5% |
11/12/2025
Event 9/30/2025
|
||
| P. Kent Hawryluk 13G/A | 4.3% |
11/14/2025
Event 9/30/2025
|
||
|
Deep Track Capital, LP
13G/A
|
3.6% |
8/14/2026
Event 6/30/2026
|
||
| Deep Track Capital, LP | 3.6% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 3.6% | |||
| David Kroin | 3.6% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 635 | $37.2 k |
| 2026 Q2 | 181 | 56.8 M | $3.08 B |
| 2026 Q1 | 164 | 53.0 M | $1.58 B |
| 2025 Q4 | 146 | 48.4 M | $1.53 B |
| 2025 Q3 | 136 | 47.8 M | $836 M |
| 2025 Q2 | 95 | 36.9 M | $421 M |
| 2025 Q1 | 80 | 35.7 M | $263 M |
| 2024 Q4 | 64 | 32.9 M | $606 M |
| 2024 Q3 | 46 | 30.3 M | $784 M |